Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.

@article{Masana2011SelectiveEO,
  title={Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.},
  author={Merc{\`e} Masana and Anal{\'i}a Bortolozzi and Francesc Casa{\~n}as Artigas},
  journal={The international journal of neuropsychopharmacology},
  year={2011},
  volume={14 1},
  pages={53-68}
}
The superior efficacy of atypical vs. classical antipsychotic drugs to treat negative symptoms and cognitive deficits in schizophrenia appears related to their ability to enhance mesocortical dopamine (DA) function. Given that noradrenergic (NE) transmission contributes to cortical DA output, we assessed the ability of NE-targeting drugs to modulate DA release in medial prefrontal cortex (mPFC) and nucleus accumbens (NAc), with the aim of selectively increasing mesocortical DA. Extracellular DA… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 82 references

Pharmacology and Experimental Therapeutics

  • S Leucht, C Corves, D Arbter, RR Engel
  • 2009

Similar Papers

Loading similar papers…